Gilead Sciences Inc Stock Price, News & Analysis

Gilead Sciences (Nasdaq:GILD) and the Elton John AIDS Foundation announced a five-year, $25 million extension of their RADIAN partnership to address the growing HIV crisis in Eastern Europe and Central Asia (EECA). The initiative aims to support local organizations and expand its geographic focus to include countries hosting Ukrainian refugees. Key highlights:

- EECA is one of the few regions where HIV is increasing, with new diagnoses up 20% and AIDS-related deaths up 34% since 2010.
- RADIAN has reached over 271,000 people with HIV services, provided 114,000+ HIV tests, and (re-)initiated 26,500+ people on antiretroviral therapy since 2019.
- The extension will focus on vulnerable populations and introduce an innovation fund for creative HIV response solutions.

This partnership aims to combat the escalating HIV crisis in EECA, exacerbated by conflict, anti-LGBTQ+ legislation, and stigma.

Gilead Sciences (GILD) reported strong Q2 2024 results with total revenue increasing 5% to $7.0 billion. Product sales excluding Veklury grew 6% year-over-year to $6.7 billion, driven by HIV, Liver Disease, and Oncology. Biktarvy sales increased 8% to $3.2 billion, while Oncology sales rose 15% to $841 million. Diluted EPS was $1.29, up from $0.83 in Q2 2023, primarily due to lower operating expenses and higher revenues. Non-GAAP diluted EPS increased to $2.01 from $1.34. The company's cash position decreased to $2.8 billion, mainly due to the $3.9 billion acquisition of CymaBay Therapeutics. Gilead updated its full-year 2024 guidance, maintaining product sales projections but adjusting EPS expectations.

Gilead Sciences is partnering with local German organizations to close the HIV diagnosis gap, particularly in rural and migrant communities. Germany has achieved 90% diagnosis and treatment rates for people living with HIV, but aims to reach the UNAIDS goal of 95% by 2025. Gilead's HIVISION100 initiative brings together 45 HIV experts to share best practices and improve testing accessibility.

One key partner, AIDS-Hilfe Krefeld, utilizes a mobile clinic to offer HIV and STI testing in resource- areas. Anja Wiese, an educator for the organization, believes that collaborative efforts can help Germany achieve 100% diagnosis rates. Gilead's innovations have transformed HIV from a fatal disease to a chronic and preventable condition for many, and the company is now focused on helping end the HIV epidemic globally.

The Center for Disease Analysis Foundation (CDA Foundation) has awarded $1.8 million in grants to 11 organizations as part of the CDAF-Relink program. This initiative aims to reconnect US-based individuals infected with hepatitis C (HCV) or hepatitis B (HBV) to care. The program is sponsored by an $8 million grant from Gilead Sciences (GILD). The second round of grants builds on the successes and lessons learned from the first round, implementing evidence-based approaches and emphasizing knowledge sharing. The goal is to link an estimated 5,400 diagnosed but untreated HCV and HBV infected individuals back into physicians' care. The third round of proposals will open in August 2024, with priority given to state health agencies.

Gilead Sciences (Nasdaq: GILD) has announced that it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after the market closes. The company's management will host a webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived for one year.

Gilead Sciences is a biopharmaceutical company with over three decades of experience in developing breakthrough medicines. The company focuses on innovative treatments for life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with its headquarters in Foster City, California.

Gilead Sciences (GILD) presented new data from its HIV treatment portfolio at AIDS 2024, emphasizing the long-term efficacy and safety of Biktarvy® and investigational treatments. Five-year data showed Biktarvy maintained high virologic suppression in Hispanic/Latine patients (100% undetectable status) and 98.1% in non-Hispanic/Latine patients. The BICSTaR study confirmed Biktarvy's effectiveness in older adults with comorbidities, with a 96% viral suppression rate at two years. ARTISTRY-1 study outcomes showcased the potential of bictegravir + lenacapavir combination for complex treatment regimens. New investigational treatments, GS-4182 and GS-1720, indicate promising once-weekly dosing options. Additionally, lenacapavir with bNAbs demonstrated sustained viral suppression with twice-yearly dosing. These comprehensive findings reinforce Gilead's commitment to innovative, person-centered HIV treatment solutions.

Gilead Sciences (GILD) announced full efficacy and safety results from its Phase 3 PURPOSE 1 trial for lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor for HIV prevention. Key findings include:

- Zero HIV infections and 100% efficacy in the lenacapavir group
- Superior prevention compared to daily oral Truvada
- High adherence (>90%) to lenacapavir injections
- Generally well-tolerated with no serious injection site reactions
- First adult pivotal HIV prevention trial to include pregnant women and adolescents

If approved, lenacapavir would be the first twice-yearly PrEP option, potentially improving uptake and adherence. Gilead is prioritizing swift access in high-incidence, resource- countries. Results from the PURPOSE 2 trial are expected in late 2024/early 2025.

Gilead Sciences (GILD) and the Elton John AIDS Foundation have extended their RADIAN partnership for five more years, investing $25 million to address the growing HIV crisis in Eastern Europe and Central Asia (EECA). The initiative aims to support local organizations and expand its geographic focus to help communities impacted by the Ukraine conflict. RADIAN has already reached over 271,000 people with HIV services and provided more than 114,000 HIV tests since 2019. The partnership will continue to tackle structural drivers of the epidemic, strengthen HIV health systems, and enhance local organizations' capacities. It will also introduce an innovation fund to support creative solutions in the region.

Gilead Sciences (Nasdaq: GILD) has announced that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company in early 2025. Dr. Parsey will continue in his role until Q1 2025 and assist with the transition. During his five-year tenure, Dr. Parsey played a important role in strengthening and diversifying Gilead's portfolio, which has more than doubled under his leadership.

The company now has 54 ongoing clinical trials across virology, oncology, and inflammation. Dr. Parsey's contributions include advancing market-leading treatments in virology and establishing Gilead's oncology pipeline. CEO Daniel O'Day praised Dr. Parsey's significant contributions and expressed confidence in the company's future growth based on the strong, diverse clinical pipeline developed during his tenure.